The Chemours
Valuation each multiple against its own 5-year range
Vs. peers Specialty Chemicals
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| The Chemours (CC) | 1.64B | -10.67 | 10.56 | 3.22% |
| Linde (LIN) | 230.84B | 33.39 | 5.86 | 1.25% |
| Ecolab (ECL) | 82.65B | 40.10 | 7.93 | 0.99% |
| Sherwin-Williams (SHW) | 82.08B | 31.25 | 20.64 | 0.94% |
| Air Products & Chemicals (APD) | 66.16B | 124.31 | 4.63 | 2.43% |
| PPG Industries (PPG) | 25.87B | 16.71 | 3.05 | 2.45% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 58.8% below Morningstar's fair value estimate.
Fair value
The Chemours Co is assigned a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 23% discount to our quantitative fair value estimate of $17.28 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The company's profitability bolsters our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's sales yield of 303.5% lies in the top 20% compared with global peers. This company has a robust ability to generate sales without much capital investment, freeing up more capital to be returned to shareholders in the long run. We believe this is a sign that shares could be undervalued.
The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's price to cash ratio of 2.7, for example, lies in the bottom 30% compared with peers globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. This characteristic further promotes our favorable price/fair value ratio.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:47:46 · For reference only, not investment advice and not tailored to your situation.
The Chemours discussion 0 comments